JRCT ID: jRCT2041240115
Registered date:30/10/2024
33-506 :Special Drug Use-Results Survey of OPDIVO
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma |
| Date of first enrollment | 23/07/2024 |
| Target sample size | 30 |
| Countries of recruitment | |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | '[Efficacy] Comprehensive improvement (the best antitumor efficacy (RECIST) for 6 months after the initiation of OPDIVO or by the end or discontinuation of the treatment) |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | Patients with unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma, who have recieved OPDIVO for the first time |
| Exclude criteria | Patients who have received OPDIVO previously |
Related Information
| Primary Sponsor | Kuro Toshihiko |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Toshihiko Kuro |
| Address | 1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan Osaka Japan 541-8526 |
| Telephone | +81-6-6222-5501 |
| kuro@ono-pharma.com | |
| Affiliation | Ono Pharmaceutical Co.,LTD |
| Scientific contact | |
| Name | Toshihiko Kuro |
| Address | 1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan Osaka Japan 541-8526 |
| Telephone | +81-6-6222-5501 |
| kuro@ono-pharma.com | |
| Affiliation | Ono Pharmaceutical Co.,LTD |